Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

Moxifloxacin

Base Information Edit
  • Chemical Name:Moxifloxacin
  • CAS No.:151096-09-2
  • Deprecated CAS:195154-07-5
  • Molecular Formula:C21H24FN3O4
  • Molecular Weight:401.438
  • Hs Code.:
  • European Community (EC) Number:604-773-0
  • UNII:U188XYD42P
  • DSSTox Substance ID:DTXSID3048491
  • Nikkaji Number:J1.495.215B
  • Wikipedia:Moxifloxacin
  • Wikidata:Q424940
  • NCI Thesaurus Code:C62052
  • RXCUI:139462
  • Metabolomics Workbench ID:42620
  • ChEMBL ID:CHEMBL32
  • Mol file:151096-09-2.mol
Moxifloxacin

Synonyms:1-cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid;Actira;Avalox;Avelox;BAY 12 8039;BAY 12-8039;BAY 128039;BAY-12-8039;BAY-128039;BAY128039;Izilox;moxifloxacin;moxifloxacin hydrochloride;Octegra;Proflox

Suppliers and Price of Moxifloxacin
Supply Marketing:Edit
Business phase:
The product has achieved commercial mass production*data from LookChem market partment
Manufacturers and distributors:
  • Manufacture/Brand
  • Chemicals and raw materials
  • Packaging
  • price
  • Matrix Scientific
  • (1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 95%
  • 25g
  • $ 2487.00
  • Matrix Scientific
  • (1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 95%
  • 5g
  • $ 829.00
  • DC Chemicals
  • Moxifloxacin >98%
  • 100 mg
  • $ 100.00
  • Crysdot
  • Moxifloxacin 98+%
  • 10g
  • $ 180.00
  • Chemcia Scientific
  • Moxifloxacin 95%
  • 25 G
  • $ 310.00
  • Biorbyt Ltd
  • Moxifloxacin >98%
  • 1 g
  • $ 615.40
  • Biorbyt Ltd
  • Moxifloxacin >98%
  • 500 mg
  • $ 414.80
  • Biorbyt Ltd
  • Moxifloxacin >98%
  • 100 mg
  • $ 277.10
  • AvaChem
  • Moxifloxacin
  • 10g
  • $ 650.00
  • AvaChem
  • Moxifloxacin
  • 1g
  • $ 119.00
Total 184 raw suppliers
Chemical Property of Moxifloxacin Edit
Chemical Property:
  • Appearance/Colour:Almost white crystalling power 
  • Vapor Pressure:4.56E-17mmHg at 25°C 
  • Melting Point:203-208 ºC 
  • Refractive Index:1.633 
  • Boiling Point:636.4 ºC at 760 mmHg 
  • PKA:6.43±0.50(Predicted) 
  • Flash Point:338.7 ºC 
  • PSA:83.80000 
  • Density:1.409 g/cm3 
  • LogP:2.76430 
  • Storage Temp.:2-8°C(protect from light) 
  • Solubility.:Acetonitrile (Slightly), DMSO (Slightly, Heated, Sonicated), Methanol (Slightly) 
  • XLogP3:0.6
  • Hydrogen Bond Donor Count:2
  • Hydrogen Bond Acceptor Count:8
  • Rotatable Bond Count:4
  • Exact Mass:401.17508442
  • Heavy Atom Count:29
  • Complexity:727
Purity/Quality:

99%MIN *data from raw suppliers

(1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 95% *data from reagent suppliers

Safty Information:
  • Pictogram(s): HarmfulXn 
  • Hazard Codes:Xn 
  • Statements: 22-40 
  • Safety Statements: 36/37 
MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:
  • Drug Classes:Antiinfective Agents
  • Canonical SMILES:COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
  • Isomeric SMILES:COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
  • Recent ClinicalTrials:An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
  • Recent EU Clinical Trials:Efficacy and safety of different antimicrobial DURATions for the treatment of infections associated with Osteosynthesis
  • Recent NIPH Clinical Trials:QT/QTc evaluation Study in Healthy Japanese Adult Male Subjects
  • Description Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer AG (initially called BAY 12-8039), used to treat a number of infections, including: respiratory tract infections, cellulitis, anthrax, intraabdominal infections, endocarditis, meningitis, and tuberculosis. It is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avelon for oral treatment. In most countries, the drug is also available in parenteral form for intravenous infusion. In the United States, moxifloxacin is licensed for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and complicated intra-abdominal infections.[5] In the European Union, it is licensed for acute bacterial exacerbations of chronic bronchitis, non-severe community-acquired pneumonia, and acute bacterial sinusitis.
  • Uses Moxifloxacin is an antibiotic for the treatment of bacterial infections like bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.
  • Therapeutic Function Antibacterial
  • Clinical Use Acute bacterial exacerbations of chronic bronchitis and community acquired pneumonia Acute bacterial sinusitis Treatment of complicated skin and soft-tissue infections caused by methicillin-susceptible Staph. aureus and Gram-negative rods (i.v. formulation) Treatment of complicated intra-abdominal infections (i.v. formulation)
  • Drug interactions Potentially hazardous interactions with other drugs Aminophylline and theophylline: possibly increased risk of convulsions. Analgesics: increased risk of convulsions with NSAIDs. Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone, disopyramide and procainamide - avoid Antibacterials: increased risk of ventricular arrhythmias with parenteral erythromycin - avoid; increased risk of ventricular arrhythmias with delamanid and telithromycin. Anticoagulants: anticoagulant effect enhanced. Antidepressants: increased risk of ventricular arrhythmias with tricyclics, citalopram, escitalopram and venlafaxine - avoid. Antihistamines: increased risk of ventricular arrhythmias with mizolastine - avoid. Antimalarials: increased risk of ventricular arrhythmias with chloroquine, hydroxychloroquine, mefloquine or quinine - avoid; avoid with artemether with lumefantrine and piperaquine with artenimol. Antipsychotics: increased risk of ventricular arrhythmias with benperidol, droperidol, haloperidol, phenothiazines, pimozide or zuclopenthixol - avoid. Antivirals: increased risk of ventricular arrhythmias with saquinavir - avoid. Atomoxetine: increased risk of ventricular arrhythmias - avoid. Beta-blockers: increased risk of ventricular arrhythmias with sotalol - avoid. Ciclosporin: some reports of increased nephrotoxicity. Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide, bosutinib, ceritinib, panobinostat and vandetanib, avoid with panobinostat and vandetanib. Pentamidine: increased risk of ventricular arrhythmias - avoid.
Technology Process of Moxifloxacin

There total 17 articles about Moxifloxacin which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:
Guidance literature:
With [BCl2(4-picoline)][AlCl4]; triethylamine; In methanol; at 85 ℃; for 6h; Reagent/catalyst; Solvent; Temperature; Catalytic behavior;
Guidance literature:
(4aS-cis)-1-cyclopropyl-7-(2,8 diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline carboxylic aid-O3,O4-bis(propyloxy-O)borate.; With hydrogenchloride; In methanol; water; at 10 - 15 ℃; for 2h; pH=1.0 - 2.0;
With ammonia; In water; at 25 - 75 ℃; for 1.25h; pH=7.5 - 8; Product distribution / selectivity;
Guidance literature:
With sodium hydroxide; In water; pH=> 11;
With hydrogenchloride; In water; pH=8.0 - 8.2; Purification / work up;
Post RFQ for Price